Several competing companies have now implanted brain-computer interfaces in dozens of paralyzed patients who can genuinely control a computer cursor, type, and communicate using only their thoughts. Synchron's device has been placed in more than fifty patients so far, and Neuralink has implanted roughly two dozen participants across several countries who have logged thousands of hours of real home use controlling a cursor and keyboard. This is real, working technology, not a demo. It is also, as of this year, still entirely investigational, with no such device yet holding full regulatory approval anywhere.

That gap between "this genuinely works for real patients in a trial" and "this is an approved, available medical device" is the useful thing to understand about brain-computer interfaces right now. The core technology has cleared a real bar. The regulatory and manufacturing path to broad availability is a separate, slower process that realistic industry timelines still measure in years.

From the Lab to the Ledger

A brain-computer interface reads electrical signals produced by neurons and translates them into commands a computer can act on, letting someone who cannot move their limbs control a cursor, type words, or operate other devices purely through intended movement signals in the brain. The companies pursuing this differ mainly in how invasive the implant itself is. Neuralink's approach involves placing a chip with many thin electrode threads directly into brain tissue through open-skull surgery, aiming for very high-resolution signal detection. Synchron's Stentrode takes a different route, threading a stent-like electrode array into a blood vessel near the brain rather than opening the skull at all, trading some signal precision for a substantially less invasive procedure and, so far, a notably low complication rate.

Both approaches are demonstrating the same core point: the brain reliably produces decodable movement-intent signals, and current hardware and software can translate them into real, functional computer control for people who have lost the ability to move or speak. What neither approach has yet done is complete the large, pivotal trials and regulatory review required for full market approval, the step that separates a promising investigational device from something a patient's doctor could actually prescribe.

Bio-Pipeline Ledger

Endovascular brain-computer interfaces (Synchron's Stentrode): mid-to-late clinical stage, investigational. Implanted in dozens of patients with a notably low reported complication rate, now preparing a pivotal trial aimed at eventual approval.

Implanted electrode-array brain-computer interfaces (Neuralink and similar devices): early-to-mid clinical stage, investigational. Demonstrated real, sustained home use for cursor and keyboard control in a smaller number of participants, with ongoing refinement of the surgical implantation process.

Non-invasive brain-computer interfaces, such as EEG-based systems worn externally: commercially available for limited uses, lower signal precision. Useful for some research and assistive applications, but generally far less capable than an implanted device for fine motor control tasks.

Speech-restoration brain-computer interfaces for people who have lost the ability to speak: active area of research, encouraging early results. A related but distinct application of the same underlying technology, at a similarly early investigational stage.

Traditional assistive communication technology, such as eye-tracking devices for paralysis: well-established, currently the standard of care. Remains the broadly available option today for many patients with severe paralysis, while implanted brain-computer interfaces continue moving through trials.

The Clinical Reality Check

What is genuinely established today is that brain-computer interfaces work as intended for a meaningful number of real patients, restoring a functional level of communication and computer control to people who had lost it. That is a legitimate, well-documented technical achievement, not a speculative promise.

What remains true is that every one of these devices is still investigational in the places doing the most advanced trials, and industry-wide realistic estimates put limited commercial availability years away, generally in the range of the late 2020s rather than anything imminent. For a patient or family considering this technology today, the honest picture is a genuinely promising, actively advancing field that is not yet something a doctor can prescribe outside of a clinical trial, with established assistive technology remaining the real, available option in the meantime.